Medication info
Elzorejet Tablet 4/10 mg

Elzorejet Tablet 4/10 mg

Prescription medicationTabletOral
Ingredient · strength
Pitavastatin Calcium›4mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202301673 · Approved 2023.05.25 · Insurance code 641908280

Summary

Main use
Improvement of primary hypercholesterolemia and mixed dyslipidemia
Who takes it
Adults
Adult dose
Administer this medicine once daily, regardless of meals. Patients must continue a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased to a maximum of 4/10mg once daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience. Use in patients with hepatic impairment: In patients with hepatic impairment, an initial dose of 1 mg once daily of pitavastatin calcium is recommended; therefore, use of this medicine (a pitavastatin calcium/ezetimibe combination) as initial therapy is not recommended. The maximum dose is 2/10mg once daily. Use of this medicine (a pitavastatin calcium/ezetimibe combination) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a pitavastatin calcium/ezetimibe combination) to patients with severe hepatic impairment.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of primary hypercholesterolemia and mixed dyslipidemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL cholesterol
  • elevated Apo B
  • elevated triglycerides
  • elevated non-HDL cholesterol.
View approved original text

This medication is used to improve blood lipid levels in patients with primary hypercholesterolemia and mixed dyslipidemia. Specifically, it helps lower total cholesterol, LDL cholesterol, Apo B protein, triglycerides, and non-HDL cholesterol levels while increasing levels of good cholesterol, HDL cholesterol. It is also used in conjunction with a dietary regimen and plays an important role in maintaining vascular health and reducing the risk of cardiovascular disease. This medication regulates lipid balance in the body to improve healthy blood lipid status.

How to take

Adult dose

Administer this medicine once daily, regardless of meals. Patients must continue a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased to a maximum of 4/10mg once daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience. Use in patients with hepatic impairment: In patients with hepatic impairment, an initial dose of 1 mg once daily of pitavastatin calcium is recommended; therefore, use of this medicine (a pitavastatin calcium/ezetimibe combination) as initial therapy is not recommended. The maximum dose is 2/10mg once daily. Use of this medicine (a pitavastatin calcium/ezetimibe combination) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a pitavastatin calcium/ezetimibe combination) to patients with severe hepatic impairment.

Precautions

This medication should not be administered to certain patients. For instance, it should not be used in patients who are allergic to its ingredients or have severe liver disease, pregnant or nursing women, and children. Additionally, it should be used cautiously in patients with impaired liver function, excessive alcohol consumption, kidney issues, muscle diseases, or in the elderly. If symptoms such as muscle pain or weakness occur during treatment with this medication, notify your doctor immediately and regular liver function tests should be performed. Since this medication is metabolized in the liver, patients with poor liver function may have an increased risk of side effects. Furthermore, serious side effects such as muscle damage or deterioration of kidney function may occur when taken with certain other medications; therefore, it is crucial to consult with a doctor or pharmacist if you are taking other medications. Pregnant women or those who may become pregnant and nursing mothers should not take this medication, and if pregnancy occurs during treatment, it should be discontinued immediately. The safety of this medication in children has not been established, so it should not be used in pediatric patients. The elderly generally do not require dosage adjustment; however, caution is needed due to possible side effects from declining physical function. In cases of overdose, since there is no specific antidote, treatment should be symptomatic, and liver function and muscle-related tests should be performed. This medication should be kept out of the reach of children, and it is advisable not to transfer it to another container.

Side effects

Abdominal pain, diarrhea, dry mouth, bloating, gastroesophageal reflux disease, toothache, increased blood creatine phosphokinase activity, increased alanine aminotransferase, increased aspartate aminotransferase, weakness, chest discomfort, fatigue, myalgia, taste disturbance, headache, urticaria, dizziness, decreased appetite, insomnia, dyspnea, constipation, dryness syndrome, rash, malaise, paralysis, pruritus, elevated γ-GT, increased plasma creatine phosphokinase levels, increased serum ALT, increased serum AST, elevated total protein, headache, myalgia, rhabdomyolysis, myopathy, liver dysfunction, jaundice, thrombocytopenia, urticaria, rash, pruritus, erythema, angioedema, elevated bilirubin, increased cholinesterase, elevated γ-GT, elevated ALP, increased LDH, stiffness, drowsiness, dizziness, thirst, dyspepsia, abdominal distention, stomatitis, vomiting, poor appetite, glossitis, nausea, epigastric discomfort, diarrhea, thrombocytopenia, granulocytopenia, leukopenia, eosinophilia, leukocytosis, elevated globulin, positive Coombs test, anemia, frequency of urination, increased BUN, elevated serum creatinine, decreased aldosterone, increased aldosterone, elevated adrenocorticotropic hormone, increased cortisol, decreased testosterone, muscle cramps, elevated myoglobin, increased CPK, myalgia, weakness, palpitations, fatigue, skin pain, burning sensation, arthralgia, edema, blurred vision, photophobia, hearing loss, hematuria, elevated uric acid, increased serum potassium and phosphorus, taste disturbance, colored urine, malaise, positive antinuclear antibody, alopecia, sleep disturbance, memory loss, depression, interstitial lung disease, sexual dysfunction, diabetes mellitus, immune-mediated necrotizing myopathy, severe muscle weakness, ocular myasthenia, facial edema, edema, arm swelling, hypersensitivity, skin paresthesia, elevated blood pressure, chest discomfort, upper respiratory infection, pharyngitis, sinusitis, cough, sputum, runny nose, limb pain, diabetic neuropathy, tremor, epigastric pain, vomiting, gastritis, epigastric discomfort, belching, gastrointestinal disorders, gastroesophageal reflux disease, tongue disorders, urticaria, sweating, rash, pruritus, anemia, splenomegaly, renal failure, liver dysfunction, increased blood creatinine, increased blood urea

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly sealed container that protects it from light. It is also recommended to store the medication at room temperature between 1°C and 30°C. Proper storage helps maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.